Artiva Biotherapeutics (ARTV) Earnings Analysis

Artiva Biotherapeutics (ARTV) has no confirmed upcoming earnings date. Last quarter (2026-05-08) it missed with EPS -0.95 USD vs -0.88 USD est (-8%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.82.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ARTV next report earnings?

No confirmed upcoming earnings date is currently scheduled for ARTV. This page updates as the calendar is published.

ARTV earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-0.95 USD-0.88 USD-8%Miss
2026-03-10-0.84 USD-0.87 USD+3.4%Beat
2025-11-12-0.88 USD-0.92 USD+4.3%Beat
2024-08-29-22 USD-4.4 USD-400%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

ARTV valuation and analyst view

Trailing P/E-2.82
Trailing EPS-3.52818 USD
Price / book2.81
Dividend yield0.00%
Market cap0.24B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target37.5 USD

Related research pages

Frequently asked questions

When is Artiva Biotherapeutics (ARTV)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for ARTV. This page updates as the calendar is published.

Did ARTV beat earnings last quarter?

In its 2026-05-08 report, ARTV posted EPS of -0.95 USD versus a -0.88 USD estimate — a miss of 8%.

What is ARTV's earnings track record?

Over the last 4 reported quarters with consensus data, ARTV beat estimates 2 times (50%).

What is ARTV's current P/E ratio and EPS?

ARTV trades at a trailing P/E of -2.82 on trailing EPS of -3.528183732994252 USD.

What do analysts rate ARTV?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 37.5 USD.